| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | 54.9 | -26.7 |
| EPS (diluted, $ a share) | $-0.24 | $-0.74 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NYSE: ARMP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Armata Pharmaceuticals, Inc.: key numbers
- Share price
- $2.99Close, Nov 16
- Market cap
- $111M
- Shares outstanding
- 37.19MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Armata Pharmaceuticals, Inc.
All →Armata Pharmaceuticals Financial Results
Armata Pharmaceuticals reported its third quarter 2026 financial results and provided an update on its AP-SA02 Phase 3 program. The company is finalizing study designs with the FDA and has completed engineering runs at its cGMP manufacturing facility to support the upcoming pivotal trial.
“We continue to advance toward our most important near-term objective: initiating the Phase 3 superiority study of AP-SA02. We have progressed from planning to establishing the operational infrastructure needed to execute a large, pivotal clinical study.”
Dr. Deborah Birx, Chief Executive Officer
“We believe the FDA’s recent Breakthrough Therapy designation further underscores AP-SA02’s clinical potential. We also appreciate the continued financial support of the U.S. Department of War (“DoW”), which comes at an important time as we prepare for this next critical stage of clinical development.”
Dr. Deborah Birx, Chief Executive Officer
Armata Pharmaceuticals Business Update
Armata Pharmaceuticals received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support the Phase 3 development of its AP-SA02 bacteriophage candidate. This incremental funding brings the total cumulative government support for the program to $32.4 million and is intended to fund activities for a pivotal superiority study in complicated S. aureus bacteremia.
- Counterparty
- U.S. Department of War
Armata Pharmaceuticals Regulatory Approval
Armata Pharmaceuticals received FDA Breakthrough Therapy designation for its AP-SA02 product candidate for the treatment of complicated S. aureus bacteremia. The designation is supported by Phase 2 data showing a 100% clinical response rate without relapse at 28 days, compared to 75% for the placebo group. This status is intended to expedite the development and review of the therapy, which could potentially become the first antibacterial treatment approved based on superiority to current standard-of-care.